Evidence map›Paper›PMID 32230912›Full record

ReviewJournal of clinical medicine2020

Prevention and Management of the Post-Thrombotic Syndrome.

Ilia Makedonov, Susan R Kahn, Jean-Philippe Galanaud

2 registry-linked trialsOpen access · goldAbstract readReview
In one paragraph

Review in Journal of clinical medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 37 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed, 2 pooled it
6.2field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04794569 phase4terminatednot on this mapstarted 2021, after this paper: background citation

Tinzaparin Lead-In to Prevent the Post-Thrombotic Syndrome Phase IV Pilot Study

TypeinterventionalSponsorSunnybrook Health Sciences CentreRan2021 to 2024Enrolled9ConditionsDeep Vein Thrombosis, Post Thrombotic SyndromeArmstinzaparin, Rivaroxaban
NCT06046807 unknown statusnot on this mapstarted 2023, after this paper: background citation

Determine the Proportion of Patients With Disabling Post Thrombotic Syndrome (Moderate or Severe) in the Long Term Within the Cohort of Patients Who Participated in the Trial CELEST Therapy.

TypeobservationalSponsorLaboratoires InnotheraRan2023 to 2023Enrolled288ConditionsPost Thrombotic SyndromeArmsPhone call
3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 99 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 3 institutions in 2 countries.

Ilia MakedonovDivision of Internal Medicine, Department of Medicine, University of Ottawa, Ottawa, ON K1H 8L6, Canada.
Susan R KahnCenter for Clinical Epidemiology, Jewish General Hospital/Lady Davis Institute, Division of Internal Medicine, Department of Medicine, McGill University, Montreal, QC H3A 1A1, Canada.
Jean-Philippe GalanaudDepartment of Medicine, Sunnybrook Health Sciences Centre and University of Toronto, Toronto, ON M4N 3M5, Canada.
Canada Research Chairs · CAMcGill University · CAUniversity of Ottawa · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The post-thrombotic syndrome (PTS) is a form of chronic venous insufficiency secondary to prior deep vein thrombosis (DVT). It affects up to 50% of patients after proximal DVT. There is no effective treatment of established PTS and its management lies in its prevention after DVT. Optimal anticoagulation is key for PTS prevention. Among anticoagulants, low-molecular-weight heparins have anti-inflammatory properties, and have a particularly attractive profile. Elastic compression stockings (ECS) may be helpful for treating acute DVT symptoms but their benefits for PTS prevention are debated. Catheter-directed techniques reduce acute DVT symptoms and might reduce the risk of moderate-severe PTS in the long term in patients with ilio-femoral DVT at low risk of bleeding. Statins may decrease the risk of PTS, but current evidence is lacking. Treatment of PTS is based on the use of ECS and lifestyle measures such as leg elevation, weight loss and exercise. Venoactive medications may be helpful and research is ongoing. Interventional techniques to treat PTS should be reserved for highly selected patients with chronic iliac obstruction or greater saphenous vein reflux, but have not yet been assessed by robust clinical trials.

Indexed as

catheter-directed thrombolysisdeep vein thrombosiselastic compression stockingslow-molecular-weight heparinspost-thrombotic syndrome

Identifiers

PMID32230912
PMCPMC7230648
OpenAlexW3013402355

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.